WO2003016497A3 - Molecules for disease detection and treatment - Google Patents

Molecules for disease detection and treatment Download PDF

Info

Publication number
WO2003016497A3
WO2003016497A3 PCT/US2002/026411 US0226411W WO03016497A3 WO 2003016497 A3 WO2003016497 A3 WO 2003016497A3 US 0226411 W US0226411 W US 0226411W WO 03016497 A3 WO03016497 A3 WO 03016497A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mddt
disease detection
molecules
polynucleotides
Prior art date
Application number
PCT/US2002/026411
Other languages
French (fr)
Other versions
WO2003016497A2 (en
Inventor
Mariah R Baughn
Monique G Yao
Anita Swarnakar
Craig H Ison
Narinder K Walia
Y Tom Tang
Shanya D Becha
Henry Yue
Ernestine A Lee
Original Assignee
Incyte Genomics Inc
Mariah R Baughn
Monique G Yao
Anita Swarnakar
Craig H Ison
Narinder K Walia
Y Tom Tang
Shanya D Becha
Henry Yue
Ernestine A Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Mariah R Baughn, Monique G Yao, Anita Swarnakar, Craig H Ison, Narinder K Walia, Y Tom Tang, Shanya D Becha, Henry Yue, Ernestine A Lee filed Critical Incyte Genomics Inc
Priority to AU2002329784A priority Critical patent/AU2002329784A1/en
Publication of WO2003016497A2 publication Critical patent/WO2003016497A2/en
Publication of WO2003016497A3 publication Critical patent/WO2003016497A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Various embodiments of the invention provide human molecules for disease detection and treatment (MDDT) and polynucleotides which identify and encode MDDT. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of MDDT.
PCT/US2002/026411 2001-08-17 2002-08-16 Molecules for disease detection and treatment WO2003016497A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002329784A AU2002329784A1 (en) 2001-08-17 2002-08-16 Molecules for disease detection and treatment

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US31311501P 2001-08-17 2001-08-17
US60/313,115 2001-08-17
US31678501P 2001-08-31 2001-08-31
US60/316,785 2001-08-31
US32340701P 2001-09-17 2001-09-17
US60/323,407 2001-09-17
US32602201P 2001-09-28 2001-09-28
US60/326,022 2001-09-28
US37070702P 2002-04-05 2002-04-05
US60/370,707 2002-04-05
US37986202P 2002-05-10 2002-05-10
US60/379,862 2002-05-10

Publications (2)

Publication Number Publication Date
WO2003016497A2 WO2003016497A2 (en) 2003-02-27
WO2003016497A3 true WO2003016497A3 (en) 2003-05-22

Family

ID=27559694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026411 WO2003016497A2 (en) 2001-08-17 2002-08-16 Molecules for disease detection and treatment

Country Status (2)

Country Link
AU (1) AU2002329784A1 (en)
WO (1) WO2003016497A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231913D1 (en) * 2001-12-07 2009-05-20 Nissui Pharm Co Ltd WITH FAT CELL DIFFERENTIATION ASSOCIATED GENE AND PROTEIN
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2006025832A1 (en) * 2004-08-31 2006-03-09 University Of North Carolina At Chapel Hill Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US11344121B2 (en) 2016-04-14 2022-05-31 The Texas A&M University System Methods of predicting preeclampsia using biomarkers
WO2022212928A1 (en) * 2021-04-02 2022-10-06 The Regents Of The University Of California Modified viruses and viral particles, methods of making, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073004A1 (en) * 2000-03-17 2001-10-04 Biowindow Gene Development Inc. Shanghai A novel polypeptide - human retinaldehyde - binding protein 39 and the polynucleotide encoding said polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073004A1 (en) * 2000-03-17 2001-10-04 Biowindow Gene Development Inc. Shanghai A novel polypeptide - human retinaldehyde - binding protein 39 and the polynucleotide encoding said polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAI ET AL.: "Functional annotation of a full-length mouse cDNA collection", NATURE, vol. 409, 8 February 2001 (2001-02-08), pages 685 - 690, XP002207921 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Also Published As

Publication number Publication date
AU2002329784A1 (en) 2003-03-03
WO2003016497A2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2003052075A3 (en) Enzymes
WO2002063005A3 (en) Lipid-associated molecules
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2003042357A3 (en) Enzymes
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2003031568A8 (en) Intracellular signaling molecules
WO2003052049A3 (en) Molecules for disease detection and treatment
WO2003063688A3 (en) Protein modification and maintenance molecules
WO2004053068A3 (en) Protein modification and maintenance molecules
WO2004009797A3 (en) Protein modification and maintenance molecules
WO2002060942A3 (en) Protein modification and maintenance molecules
WO2004044165A3 (en) Lipid-associated proteins
WO2003031595A3 (en) Molecules for disease detection and treatment
WO2002101008A3 (en) Intracellular signaling molecules
WO2003031939A3 (en) Protein modification and maintenance molecules
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2003046152A3 (en) Molecules for disease detection and treatment
WO2002078420A3 (en) Molecules for disease detection and treatment
WO2003100016A3 (en) Protein modification and maintenance molecules
WO2003010329A3 (en) Nucleic acid-associated proteins
WO2002046413A3 (en) Molecules for disease detection and treatment
WO2002064792A3 (en) Molecules for disease detection and treatment
WO2003093427A3 (en) Molecules for disease detection and treatment
WO2003083084A3 (en) Protein modification and maintenance molecules
WO2002070709A3 (en) Molecules for disease detection and treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP